Mersana Therapeutics Added to NASDAQ Biotechnology Index
December 15 2017 - 8:00AM
Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody drug conjugates (ADCs) based on its
proprietary Dolaflexin® platform, today announced that it has been
selected for addition to the NASDAQ Biotechnology Index®
(Nasdaq:NBI). Mersana’s addition to the NBI will become effective
prior to market open on Monday, December 18th, 2017.
The NASDAQ Biotechnology Index (NBI) contains securities of
NASDAQ-listed companies that meet certain eligibility criteria, and
are classified according to the Industry Classification Benchmark
as either biotechnology or pharmaceuticals. The NASDAQ
Biotechnology Index is re-ranked annually. For more
information about the NASDAQ Biotechnology Index visit
https://indexes.nasdaqomx.com.
About Mersana Therapeutics Mersana Therapeutics
is a clinical-stage biopharmaceutical company using its
differentiated and proprietary ADC platforms to develop highly
targeted drugs with increased tolerability and expanded
opportunities to deliver meaningful clinical benefit to
patients. Mersana’s lead product candidate, XMT-1522, is in
Phase 1 clinical trials in patients with advanced tumors expressing
HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC)
and gastric cancer patients. The Company’s second product
candidate, XMT-1536, is in Phase 1 clinical trials in patients with
tumors expressing NaPi2b, including ovarian cancer, NSCLC and other
cancers. In addition, multiple partners are using Mersana’s
platform to advance their ADC pipelines.
Forward-Looking Statements This press release
contains “forward-looking” statements within the meaning of federal
securities laws. These forward-looking statements are not
statements of historical facts and are based on management’s
beliefs and assumptions and on information currently available to
management. Forward-looking statements include information
concerning the design of its clinical trials. Forward-looking
statements generally can be identified by terms such as
“anticipates,” “believes,” “could,” “seeks,” “estimates,”
“intends,” “may,” “plans,” “potential,” “predicts,” “projects,”
“should,” “will,” “would” or similar expressions and the negatives
of those terms. Forward-looking statements represent management’s
beliefs and assumptions only as of the date of this presentation.
The Company’s operations involve risks and uncertainties, many of
which are outside its control, and any one of which, or combination
of which, could materially affect its results of operations and
whether the forward-looking statements ultimately prove to be
correct. Factors that may materially affect the Company’s
results of operations include, among other things, that preclinical
testing may not be predictive of the results or success of ongoing
or later preclinical or clinical trials and that the development of
the Company’s product candidates will take longer and/or cost more
than planned, as well as those listed in the Company’s Quarterly
Report on Form 10-Q filed on November 13, 2017 with the Securities
and Exchange Commission (“SEC”). Except as required by law, the
Company assumes no obligation to update these forward-looking
statements publicly, or to update the reasons actual results could
differ materially from those anticipated in the forward-looking
statements, even if new information becomes available in the
future.
Copies of the Company’s our Quarterly Report on Form 10-Q and
our other SEC filings are available by visiting EDGAR on
the SEC website at http://www.sec.gov.
Contacts:
Media ContactPaul Kidwell,
617-680-1088paulkidwell@mersana.com
or
Investors ContactStern Investor Relations, Inc.Christina
Tartaglia, 212-362-1200christina@sternir.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Sep 2023 to Sep 2024